Vital Specialized Biopharmaceutical Insights and Analytics

for Experts from Experts

BioTrends is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Featured Report
PatientTrends: Rheumatoid Arthritis US

Although there are many treatments available for RA, there is still a high unmet need for new treatments, especially for patients who are refractory to current therapies, such as TNF-alpha inhibitors, the most widely used biologic agents in RA.
Learn More

New Product 
ChartTrends: Chronic Kidney Disease: Non-Dialysis - Renal Anemia 2014 (China)

By comparing what nephrologists report about patient care dynamics to actual treatment records in CKD-ND, gaps in intended care versus actual care are uncovered and patient segments become more clearly defined. This new report covers patient demographics, referral patterns, length of treatment, blood transfusion rates, hospitalization rates and common reasons for referral in the Chinese market.
Learn More

Search Published Reports

TOP TEN REPORTS

See which reports have been searched on the most.

Go

In the Spotlight

Special Report: The Impact of New Iron- Based Phosphate Binders on the Hyperphosphatemia Market

In this new report, surveyed U.S. nephrologists indicate that there is a high perceived need for new phosphate binders to treat hyperphosphatemia.

Download

View sample slides from this report to learn more about our analysis of nephrologists’ practice patterns, attitudes and perceptions of the projected use of various phosphate binders.


Recent Reports [ view all ]

  • EU5 Market Access Opportunities and Challenges for Current and Emerging Rheumatoid Arthritis Agents Amid the Launches of Oral Jak Inhibitors and Biosimilars

    Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation... Read More

  • What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe? A Study of EU5 Prescribers and Payers

    In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus... Read More

  • Hospital-Treated Infections (Event Driven)

    Last Updated 18 December 2013
    Hospital-treated infections (HTIs) constitute a high-value segment of the... Read More

Decision Resources Group brands include: